IGENEON
Igeneon was a Vienna-based drug discovery company focused on cancer immunotherapy.
IGENEON
Industry:
Biotechnology Health Care Life Science Medical
Founded:
1999-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.igeneon.com
Status:
Active
Technology used in webpage:
SPF Amazon Amazon Virginia Region Amazon Ohio Region NameBright Confluence Networks Open Thumbnails
Similar Organizations
Human Tissue Authority
Human Tissue Authority
ImmunoGenesis
ImmunoGenesis specializes in science-driven immune therapies for tumor treatment.
Myovec
Myovec is a company specialized in gene therapy.
Nova Science
Nova Science was established in 1999 by Jim Coleman, the previous founder of Chiroxia.
Current Employees Featured
Founder
Official Site Inspections
http://www.igeneon.com
- Host name: ec2-3-130-253-23.us-east-2.compute.amazonaws.com
- IP address: 3.130.253.23
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "Igeneon"
Igeneon - Crunchbase Company Profile & Funding
Organization. Igeneon . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Igeneon specializes in cancer immunotherapy. Acquired by . …See details»
Igeneon Company Profile 2024: Valuation, Investors, Acquisition
Igeneon General Information Description. Operator of a biopharmaceutical company focusing on the development of cancer immunotherapy products. The company focuses on the …See details»
Igeneon - Products, Competitors, Financials, Employees, …
Igeneon. Frequently Asked Questions (FAQ) When was Igeneon founded? Igeneon was founded in 1999. Where is Igeneon's headquarters? Igeneon's headquarters is located at Brunner …See details»
Igeneon AG - Drug pipelines, Patents, Clinical trials - Synapse
Explore Igeneon AG with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Neoplasms, Technology Platform:Vaccine, Drug:IGN ...See details»
Press Release - SEC.gov
“The acquisition of Igeneon by Aphton is an important event for both companies,” stated Dr. Manfred Ruediger, Chief Executive Officer of Igeneon. “We expect that the resulting …See details»
Aphton Corporation to Acquire Igeneon Extending its Leadership
Igeneon offers a promising pipeline with late-stage products and an experienced research and development organization. Igeneon’s pipeline significantly augments Aphton’s late-stage …See details»
Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M
Dec 16, 2004 Along with the two clinical-stage products and a number of preclinical research projects, Aphton will gain Igeneon's 60 employees, essentially doubling the combined …See details»
Aphton Corporation to Acquire igeneon - bionity.com
Mar 24, 2005 With the signing of this transaction, Aphton takes a significant step toward implementing its strategy of expanding its oncology-focused business. igeneon offers a …See details»
Igeneon - Tech Company Profile - Gaebler.com Venture Capital …
Igeneon, is a clinical stage biopharmaceutical company focused on the development of active and passive cancer immunotherapies designed to prevent or delay the development of metastases …See details»
Igeneon - Crunchbase
Igeneon specializes in cancer immunotherapy.See details»
Igeneon - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Igeneon specializes in cancer immunotherapy.See details»
Igeneon - Company Profile - Tracxn
Oct 30, 2024 Igeneon ranks 1,631st among 2408 active competitors. 870 of its competitors are funded while 548 have exited. Overall, Igeneon and its competitors have raised over $80.3B in …See details»
IGN-402 - Drug Targets, Indications, Patents - Synapse - Patsnap
IGN-402, Initially developed by Igeneon AG, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active Org.: Igeneon AG. …See details»
Igeneon Management Team - CB Insights
Explore {Igeneon's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. Igeneon CEO, Founder, Key …See details»
IGN-201 - Drug Targets, Indications, Patents - Synapse - Patsnap
IGN-201: a Immunostimulants Drug, Initially developed by Igeneon AG, Now, its global highest R&D status is Discontinued, Mechanism: Immunostimulants, Therapeutic Areas: Neoplasms. …See details»
Igeneon - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Igeneon . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Igeneon has 1 current …See details»
Companies Announce Commercialization And Manufacturing …
Jul 25, 2005 Aphton Corporation, and VaxGen's joint venture Celltrion, Inc. announced recently that Aphton's wholly-owned subsidiary Igeneon signed a licensing and commercialization …See details»
Research programme: immunoregulatory vaccines - igeneon
Igeneon (Aphton Corporation) was developing immunoregulatory vaccines based on polyclonal immunoglobulins for the treatment of cancer, allergy and autoimmune ... If your organization …See details»
Igeneon: Staying Close to Home - insights.citeline.com
Nov 1, 2002 Igeneon's latest in-licensing rounds out its cancer immunotherapy pipeline with another compound its founders know well. IGN 301, an epithelial cancer vaccine, is the …See details»
Geneon Universal Entertainment - Audiovisual Identity Database
Nov 21, 2024 Background. Geneon Entertainment was formed in 2003 after Pioneer sold off its entertainment division to another Japanese giant conglomerate known as Dentsu.The new …See details»